Enliven Therapeutics ELVN EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's EPS (diluted)?
- Enliven Therapeutics (ELVN) reported EPS (diluted) of -$0.38 in Q1 2026.
- How has Enliven Therapeutics's EPS (diluted) changed year-over-year?
- Enliven Therapeutics's EPS (diluted) increased by 33.3% year-over-year, from -$0.57 to -$0.38.
- What is the long-term trend for Enliven Therapeutics's EPS (diluted)?
- Over 4 years (2021 to 2025), Enliven Therapeutics's EPS (diluted) has grown at a -12.0% compound annual growth rate (CAGR), from -$3.10 to -$1.86.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.